Melissa Baird, the Chief Operating Officer of Hims & Hers Health, Inc. (NYSE:HIMS), has recently sold a significant portion of her holdings in the company. According to a recent SEC filing, Baird sold ...

Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest ...

We recently published a list of 10 Firms Post Double-Digit Gains on Thursday. In this article, we are going to take a look at ...

Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug boom, surged 28% on Thursday ...

Hims & Hers Health (NYSE: HIMS) is surging today. The stock is up 19%, and this is part of a broader 482.5% rally in the past year that has carried this telehealth company to nosebleed levels. Here’s ...

Hims & Hers Health (HIMS) stock hit a new all-time high on Thursday as retail investors have taken interest in the telehealth ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...